Gynecomastia

Gynecomastia is the benign proliferation of glandular breast tissue in males, driven by any change in the local balance between estrogen and androgen effect at the breast — estrogen stimulates ductal epithelial proliferation, ductal elongation and branching, and periductal fibroblast proliferation, while androgens normally oppose these effects. An imbalance favouring estrogen can arise from increased estrogen production, decreased androgen production, decreased androgen action (receptor blockade or reduced conversion to more potent androgens), or increased peripheral conversion of androgen to estrogen by aromatase, particularly in adipose tissue.^[1][2][3]

Physiologic gynecomastia clusters at three predictable life stages. Neonatal gynecomastia is common and transient, driven by transplacental exposure to maternal and placental estrogen, and resolves within weeks as maternal hormone clears the infant's circulation.^[1] Pubertal gynecomastia is genuinely very common — affecting up to 60% of boys by around age 14 — reflecting a relative excess of estradiol before testicular testosterone production has fully risen; the large majority resolve spontaneously within about 2-3 years without any treatment.^[1] Senescent (age-related) gynecomastia affects an estimated 36-57% of men over 60, driven by a combination of declining testosterone production, increased peripheral aromatization in expanding adipose tissue, and the greater burden of polypharmacy and comorbidity that comes with age.^[1]

Beyond these physiologic peaks, a substantial share of adult-onset gynecomastia is drug-induced — and, unlike many of the underlying endocrine causes it can mimic, it is often genuinely reversible once the causative agent is identified and addressed. This makes medication review the single highest-value action a pharmacist can take for this presentation, and it is the organizing focus of this chapter.^[3][2]

Pathophysiology — the estrogen:androgen balance

Breast tissue in males, as in females, responds to the local balance of estrogen and androgen signalling. Estrogen drives ductal epithelial proliferation, elongation, and branching, along with periductal fibroblast proliferation and increased vascularity; androgens normally restrain this growth. Any of the following can tip that balance toward net estrogen effect and trigger glandular proliferation: increased estrogen production (a testicular, adrenal, or other estrogen-secreting source, or exogenous exposure); decreased androgen production (primary or secondary hypogonadism); decreased androgen action (androgen-receptor blockade, or reduced conversion of testosterone to the more potent dihydrotestosterone); or increased peripheral aromatization of androgen to estrogen, which rises with age and with increasing adipose tissue mass.^[1][2][3]

The pharmacist-critical drug-induced etiology list — organized by mechanism

A careful medication history is the single most useful step in this presentation. The list below is organized by mechanism, since understanding why a drug causes gynecomastia helps predict which alternative might avoid it.

• Estrogenic effects — digoxin, through a structural similarity to steroid hormones that gives it weak estrogen-like activity, is a recognized, longstanding cause; direct estrogen exposure (from a prescribed estrogen product, or inadvertent topical transfer from a partner's or family member's estrogen-containing cream or patch) works by the same mechanism, just more directly.^[1][4]
• Antiandrogens — spironolactone combines anti-androgen receptor activity with weak estrogen-agonist activity, producing dose-related gynecomastia reported in up to around 10% of patients at commonly used antihypertensive doses, rising further at the higher doses used for other indications (for example, resistant hypertension or heart failure).^[1] Finasteride and dutasteride, 5-alpha-reductase inhibitors used for benign prostatic hyperplasia and androgenetic alopecia, block the conversion of testosterone to the more potent dihydrotestosterone, shifting the local estrogen:androgen ratio at the breast even though total testosterone is unchanged.^[1] Bicalutamide and flutamide, non-steroidal antiandrogens used in prostate cancer treatment, cause gynecomastia and breast pain so frequently — up to around 85% of patients on high-dose bicalutamide without any preventive measure, per a 2025 pooled meta-analysis of 18 randomized controlled trials — that it is a well-known, expected, and genuinely counseled-for effect of this drug class, not an unusual reaction; the same applies to the GnRH agonists (e.g., leuprolide acetate, goserelin) used for androgen-deprivation therapy in prostate cancer, which lower testosterone while peripheral aromatization of the remaining androgen continues.^[5][1] See Special Populations for the proactive counseling and prophylaxis this warrants.
• Drugs disrupting testosterone synthesis or action — ketoconazole inhibits enzymes in both testicular and adrenal steroidogenesis, lowering testosterone production and shifting the ratio toward estrogen effect.^[1][4]
• Other implicated agents — omeprazole and other proton pump inhibitors are reported causes, though the evidence is weaker and largely case-report level, with no clearly established mechanism; risperidone and other dopamine-antagonist antipsychotics cause gynecomastia (and can cause galactorrhea in both sexes) through drug-induced hyperprolactinemia, which suppresses gonadotropin-releasing hormone and gonadotropin secretion while also directly stimulating breast tissue; calcium channel blockers (verapamil is the most frequently reported, though other agents in the class have also been implicated) are reported causes with an unclear mechanism and generally weak evidence; HAART/antiretroviral regimens, particularly those containing efavirenz, are associated with gynecomastia; and anabolic-androgenic steroid use, and especially its withdrawal, causes gynecomastia both through peripheral aromatization of the exogenous steroid to estrogen while using it, and through a period of suppressed endogenous testosterone production immediately after stopping.^[1] This last category is a particular concern in adolescents and young men, alongside marijuana, heroin, and amphetamine use, all of which have been linked to gynecomastia and should be screened for directly.^[6]

Reported gynecomastia incidence rises with dose for two of the medications most frequently implicated in this chapter — spironolactone and bicalutamide — a reminder that drug-induced gynecomastia is often a genuinely dose-dependent, and therefore dose-adjustable, adverse effect. (Medgirl131, CC BY-SA 4.0, Wikimedia Commons)

True gynecomastia vs. pseudogynecomastia vs. breast cancer — the exam that matters

Examine using the pinch (glide) technique: place the thumb and forefinger laterally on either side of the nipple-areolar complex and gently bring them together, gliding toward the nipple.

• True gynecomastia — a firm or rubbery, mobile, concentric (disc-shaped) mass of genuine ductal/glandular tissue, symmetrically centered directly beneath the nipple-areolar complex.^[2][4]
• Pseudogynecomastia — soft, uniformly fatty tissue with no discrete palpable disc and no true glandular proliferation, closely associated with obesity/overweight. Distinguishing this from true gynecomastia is a genuinely important clinical distinction, since it changes the entire management path — weight management and reassurance rather than a medication review and hormone workup.^[2][1]
• Breast cancer — rare in men, but the reason this exam technique matters. Findings that point away from benign gynecomastia and toward malignancy: unilateral presentation, a mass that is hard, fixed (not mobile), and irregular or eccentric (off-center, rather than the concentric disc of true gynecomastia), skin changes (dimpling, retraction, ulceration), nipple retraction or new nipple/areolar skin change, spontaneous nipple discharge (especially unilateral or blood-stained), and palpable axillary lymphadenopathy.^[4][2]

• Puberty — a transient midpubertal estrogen:testosterone imbalance affects up to 60% of boys by around age 14 and resolves spontaneously in the large majority within about 2-3 years.^[1]
• Advancing age — declining testosterone production combined with rising peripheral aromatization of androgen to estrogen in adipose tissue; affects an estimated 36-57% of men over 60.^[1]
• Obesity — increases peripheral aromatase activity and estrogen production, and is also the dominant driver of pseudogynecomastia, which makes the true-vs-pseudo distinction harder on exam alone in this group.^[1]
• A recent start or dose change of any of the causative medications above — spironolactone, finasteride/dutasteride, bicalutamide/flutamide, a GnRH agonist, ketoconazole, a PPI, an antipsychotic, a calcium channel blocker, an antiretroviral, or digoxin.
• Chronic liver disease/cirrhosis — reduced hepatic clearance of estrogen, plus increased peripheral aromatization.
• Chronic kidney disease, including hemodialysis — altered gonadal hormone metabolism and clearance.
• Hyperthyroidism — raises sex-hormone-binding globulin, altering the free testosterone:estradiol ratio available to breast tissue.
• Hypogonadism of any cause (primary testicular failure, Klinefelter syndrome, or pituitary/hypothalamic disease) — reduced androgen production shifts the balance toward estrogen effect. Klinefelter syndrome specifically also carries a markedly elevated (20- to 50-fold) risk of male breast cancer, which lowers the referral threshold for any new or changing breast finding in this population.^[1]
• Recreational substance use — marijuana, heroin, and amphetamines — and anabolic-androgenic steroid use or withdrawal, particularly in adolescents and young men.^[6]
• A rare hormone-secreting tumor — a testicular Leydig or Sertoli cell tumor, an adrenal tumor, or an hCG-secreting tumor (some germ cell or lung tumors).

History

• Onset and duration — this matters clinically, not just administratively: gynecomastia tissue passes through a florid stage (roughly the first 4 months, with active ductal proliferation and increased vascularity that responds well to a reversible cause being addressed or to medical therapy), an intermediate stage (around a year), and a fibrous stage (beyond about a year, with dense stroma and few remaining ducts) that responds poorly to anything but surgery — so a duration beyond about a year is itself a clinically meaningful finding.^[4]
• Pain or tenderness, whether unilateral or bilateral, and the rate of growth.
• A complete medication history — prescription, over-the-counter, herbal/supplement, and recreational — specifically screening the causative list in Recognize the Condition.
• Review of systems for hypogonadism symptoms (decreased libido, erectile dysfunction, reduced body/facial hair), hyperthyroidism, liver or renal disease, and unexplained weight change.
• In adolescents, a pubertal-stage and sexual-development history; in any patient, a history of testicular trauma, mumps orchitis, or cryptorchidism.

Examination

• The pinch/glide technique described in Recognize the Condition, to distinguish a true concentric glandular disc from pseudogynecomastia's diffuse fatty tissue or from a red-flag finding.
• A testicular exam — size, symmetry, and any mass — should not be skipped; a testicular mass is the single finding most specifically suggestive of a hormone-secreting tumor as the underlying cause.^[2][1]
• Signs of hyperthyroidism, hypogonadism, hepatic disease, or chronic kidney disease.

When to investigate vs. when clinical exam is enough

Both the EAA guideline and the major American reviews converge on a stepwise, exam-driven approach rather than routine testing for every patient.^[7][2][1]

• Physiologic pubertal gynecomastia, or gynecomastia with a clear, recently-started causative drug, and a normal exam with no red flags — clinical history and examination alone are sufficient; no laboratory workup is needed.^[1][7]
• Adult-onset gynecomastia with no clear reversible cause, or with any red-flag/hypogonadism/thyroid/hepatic/renal finding on history or exam — obtain a hormone panel (total testosterone, estradiol, LH, prolactin, TSH) plus liver and renal function tests.^[2][7][1]
  • Low testosterone with a high LH suggests primary (testicular) hypogonadism; low testosterone with a low or inappropriately normal LH suggests secondary (central) hypogonadism and warrants pituitary imaging.
  • Elevated prolactin suggests hyperprolactinemia — check first for a causative drug (see Recognize the Condition) before pursuing pituitary imaging for a prolactinoma.
  • Elevated estradiol with a low testosterone and low LH suggests a peripheral estrogen-producing source (an adrenal or testicular tumor, or exogenous exposure) rather than a primary gonadal or pituitary problem.
  • An elevated hCG, if measured, suggests a germ cell or other hCG-secreting tumor.^[2][1]
• Imaging and biopsy are reserved for exam findings suspicious for malignancy (see Red Flags) — diagnostic breast ultrasound and/or mammography, with biopsy if a suspicious mass is confirmed. Imaging is not needed for typical, bilateral, concentric, tender gynecomastia with an identified reversible cause.^[2][7]
• Testicular ultrasound if a testicular mass is found on exam, or if labs suggest a peripheral estrogen- or hCG-producing source.

• Identify and, where possible, reverse an underlying cause before adding any new treatment — this is the single highest-value pharmacist action, since most drug-induced gynecomastia is genuinely reversible with discontinuation or dose reduction of the causative agent.
• Distinguish physiologic, self-limited gynecomastia (neonatal, pubertal, early drug-induced) from disease that genuinely needs workup, so patients who need only reassurance are not over-investigated and patients who need referral are not reassured inappropriately.
• Coordinate any medication change with the prescriber rather than recommending unilateral discontinuation — especially when the causative drug is clinically necessary and not easily substituted, such as an antipsychotic controlling active psychosis, or bicalutamide/a GnRH agonist treating prostate cancer.
• Relieve pain and tenderness, and reduce breast tissue volume, for patients whose gynecomastia is persistent and bothersome — but only using medical therapy within its real evidence base (early, painful, non-fibrotic disease), not for longstanding fibrotic tissue where it has little chance of working.
• Act within the "window" while tissue is still in its early, medically-responsive (florid/intermediate) stage, since untreated gynecomastia can progress to a fibrotic, medically-unresponsive stage over about a year.
• Recognize and refer promptly for any finding suspicious for breast cancer.
• Explicitly acknowledge the real psychosocial impact of gynecomastia — embarrassment, avoidance of swimming, sports, or intimacy, anxiety — rather than treating this as only a physical-exam-and-algorithm problem, particularly in adolescents.

• Reassurance and explicit education, especially for adolescents — that pubertal gynecomastia is extremely common (up to 60% of boys) and resolves on its own within a few years in the large majority of cases.^[1] This alone resolves much of the associated anxiety, and should be stated directly rather than left implicit.
• Weight management where obesity/pseudogynecomastia is contributing — reduces peripheral aromatization and the fatty component of breast enlargement, though it will not reduce a true firm glandular disc.^[1]
• Discontinuing or substituting a recreational substance (alcohol, marijuana, anabolic-androgenic steroids, heroin, amphetamines) where implicated, with appropriate substance-use counseling or referral.^[6]
• Set a defined time limit for any medical therapy trial (e.g., 3-6 months of tamoxifen) so a bothersome, non-fibrotic case has a clear decision point rather than drifting untreated into fibrotic, treatment-resistant disease.
• Psychosocial support — screen for and directly acknowledge embarrassment, social avoidance, and anxiety or low mood, particularly in adolescent boys, for whom gynecomastia can meaningfully affect quality of life. A brief, direct acknowledgment from the pharmacist is itself a valuable intervention.
• Surgical referral (reduction mammoplasty, liposuction, or a combination) for fibrotic, longstanding, or persistently bothersome gynecomastia unresponsive to medication review and/or a medical therapy trial — the definitive treatment once glandular tissue has fibrosed.^[4]

Adolescents / pubertal boys

Pubertal gynecomastia is very common — affecting up to 60% of boys by around age 14 — and typically resolves within about 2-3 years.^[1] Referral is for atypical features specifically: very early (prepubertal) onset, other signs of precocious puberty, marked or asymmetric enlargement (macromastia), rapid progression, or significant family/psychosocial distress that warrants an earlier medical (tamoxifen trial) or surgical discussion rather than continued watchful waiting.^[6] Screen adolescents directly for anabolic-androgenic steroid, marijuana, heroin, and amphetamine use, all of which have been linked to gynecomastia in this age group.^[6]

Neonates

Transient gynecomastia from transplacental maternal and placental estrogen exposure resolves within weeks; reassurance to caregivers is generally all that is needed.^[1]

Older adults

Senescent gynecomastia is common (an estimated 36-57% of men over 60).^[1] The greater polypharmacy burden and higher background rate of comorbid liver disease, renal disease, and hypogonadism in this group make a thorough medication and comorbidity review especially valuable before attributing new gynecomastia to age alone.

Patients on antiandrogen or GnRH-agonist therapy for prostate cancer

Gynecomastia and breast pain are well-known, expected effects of bicalutamide and flutamide — occurring in up to around 85% of patients on high-dose bicalutamide with no preventive measure, per a 2025 meta-analysis of 18 randomized controlled trials — and are also seen with GnRH agonists.^[5] This is a genuine counseling opportunity: raise it before therapy starts rather than waiting for the patient to report symptoms, and discuss prophylactic tamoxifen (which reduced the relative risk of breast events by roughly 82% in pooled trial data) or prophylactic breast-area radiotherapy (roughly 52% relative risk reduction for gynecomastia) with the oncology team at treatment initiation.^[5] Do not recommend stopping antiandrogen or GnRH-agonist therapy for gynecomastia alone, given its role in cancer control — refer any question about the anticancer regimen itself back to oncology.

Patients on antipsychotics

Hyperprolactinemia-driven gynecomastia (and possible galactorrhea) can occur with risperidone and other dopamine-antagonist antipsychotics.^[1] Discuss a dose reduction or a switch to a lower-prolactin-liability agent with the prescriber, weighing the psychiatric necessity of the current regimen before recommending any change.

Klinefelter syndrome

Gynecomastia is very common in this population and carries a markedly elevated (20- to 50-fold) risk of male breast cancer relative to the general male population — apply a lower threshold for referral for any new or changing breast finding.^[1]

Renal and hepatic impairment

Chronic kidney disease (including hemodialysis) and chronic liver disease/cirrhosis are themselves independent causes of gynecomastia, through altered sex-hormone metabolism and clearance — consider these as a driving cause in their own right, not only as a modifier of medication-induced gynecomastia. Tamoxifen is hepatically metabolized; use it cautiously and with specialist input in significant hepatic impairment.

For physiologic (neonatal or pubertal) gynecomastia managed with reassurance, no laboratory follow-up is needed. A brief follow-up conversation in a few months, to confirm expected improvement and to address any ongoing anxiety, is reasonable, particularly for a self-conscious adolescent.

• For suspected drug-induced gynecomastia after a medication change: confirm the change was actually made by the prescriber, and follow up to confirm tenderness and size are trending down over the following weeks to months rather than assuming success without checking.
• For a tamoxifen trial: reassess pain and size at approximately 4-6 weeks and again at the end of the planned 3-6 month course. A lack of any response by mid-course is the point to reconsider the diagnosis — has the tissue already fibrosed, or was a red-flag or endocrine cause missed? — rather than extending the trial indefinitely.
• Counsel explicitly that untreated, persistent gynecomastia can progress from the medically-responsive florid/intermediate stage to the largely unresponsive fibrous stage over about a year — this is the practical reason a bothersome case should not simply be "watched" indefinitely without a documented follow-up plan.^[4]
• Document the suspected or confirmed cause, what has been tried, and the response — especially relevant for a patient on long-term antiandrogen or antipsychotic therapy, where gynecomastia may be a recurring topic across visits.
• Screen explicitly for the psychosocial impact (embarrassment, avoidance of swimming, sports, or intimacy, anxiety, low mood) at follow-up, not only the physical exam — this remains a real complication of unresolved gynecomastia, especially in adolescents, independent of tissue size alone.

1. No improvement in physiologic or drug-induced gynecomastia after the expected timeframe (pubertal: no improvement over about 2-3 years; drug-induced: no improvement several months after the causative agent is stopped or changed): re-examine specifically for a fibrotic disc, and reconsider whether the original diagnosis and workup missed something.
2. No response to a 3-6 month tamoxifen trial: reassess for fibrosis on exam — a longstanding or firm, minimally compressible disc explains treatment failure — and refer for surgical evaluation, rather than extending the trial or switching to anastrozole by default given its own still-weaker evidence for this indication.
3. A causative drug cannot be safely stopped or changed (e.g., an antipsychotic controlling active psychosis, or antiandrogen/GnRH-agonist therapy for prostate cancer): discuss prophylactic tamoxifen, or radiotherapy in the prostate-cancer context, with the prescribing team rather than treating this as an unmanageable situation.
4. New or worsening red-flag findings at any point during follow-up, even in a patient with a previously reassuring workup: treat as a new presentation and refer promptly, rather than assuming it is simply progression of known benign gynecomastia.
5. Persistent, significant psychosocial distress despite reassurance and/or medical therapy, in the absence of a red flag: refer for surgical consultation — impact on quality of life is itself a legitimate reason for definitive treatment, not only tissue size.
6. Abnormal hormone panel findings (for example, low testosterone with an elevated LH, or an elevated prolactin/estradiol with no identified causative drug): refer to endocrinology for further workup of an underlying pathologic cause (primary hypogonadism, a prolactinoma, or a hormone-secreting tumor) rather than continuing to treat empirically as idiopathic.

• Treating all male breast enlargement as "gynecomastia" without the pinch/glide exam to rule out pseudogynecomastia — the two need genuinely different management, and this distinction is often skipped.
• Presenting tamoxifen as an established, strongly-evidenced first-line therapy without the caveat that a formal 2019 European guideline recommends against routine use given overall low-quality trial evidence — frame it honestly as a reasonable off-label trial, not a proven standard.
• Starting or continuing a tamoxifen or anastrozole trial in longstanding, fibrotic gynecomastia, where medical therapy has little biological chance of working — refer to surgery instead of extending a trial that is unlikely to succeed.
• Recommending a patient unilaterally stop a necessary antipsychotic, antiandrogen, or GnRH-agonist medication for gynecomastia without involving the prescriber, especially when that drug is treating active psychosis or prostate cancer.
• Missing the opportunity to proactively counsel a patient starting bicalutamide or another antiandrogen/GnRH-agonist prostate cancer therapy about the high expected incidence of gynecomastia and breast pain, and the option of prophylactic tamoxifen or radiotherapy — waiting for the patient to report symptoms rather than raising it up front.
• Reassuring a patient with a unilateral, hard, fixed, or irregular mass, a skin/nipple change, or an axillary node as "just gynecomastia" without referral — male breast cancer is rare but real, and these findings change the workup regardless of how common benign gynecomastia is.
• Ordering a full hormone panel and imaging routinely for a straightforward pubertal or recently drug-induced case with a normal exam and no red flags — this is not indicated and adds cost and anxiety without benefit.
• Overlooking the real psychosocial impact of gynecomastia, particularly in adolescents, by focusing only on the physical exam and treatment algorithm.
• Missing Klinefelter syndrome as a specific reason to lower the referral threshold for a changing breast finding, given its markedly elevated (20- to 50-fold) male breast cancer risk.

How to use this table: doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Medical Therapy — Persistent, Non-Fibrotic Gynecomastia (Off-Label)

Reserved for pain or bothersome breast tissue that persists despite addressing any reversible cause, in disease that is still early (roughly under a year, not yet fibrotic on exam). Evidence overall is low-quality; a formal European guideline (EAA 2019) recommends against routine use — present as a reasonable off-label trial, not an established first-line drug.

Symptomatic Analgesia for Tenderness

Addresses pain only — neither agent reduces breast tissue volume, so pair with identifying and addressing the underlying cause.